FindTrial
Sign In

A phase II/III study of SYR-322 in subject with diabetes

-

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220871
Enrollment
Unknown
Registered
2009-09-24
Start date
2009-09-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

investigational material(s) Generic name etc : SYR-322 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : O

Sponsors

Takeda Pharmaceutical Company Limited
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The subject who is capable of providing consent to participate in this study, with ability to read and understand the informed consent form and other written information, etc.

Exclusion criteria

Exclusion criteria: 1.The subject with serious cardiac disease, cerebrovascular disorder, or serious pancreatic or hematological disease, etc. 2.The subject who is considered ineligible to participate in the study by the investigator or subinvestigator, etc.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026